Auxilium Pharmaceuticals Inc: (NASD: AUXL)

$17.34

0.10 (0.58%)

Volume 588,146

Jun 18 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		16.95 - 17.39
	
		52wk Low - High
		13.87 - 29.37
	
		Previous Close
		17.24
	
		Avg. Volume
		771,252
	
		Industry
		MED-DRUGS
	
		Market Cap
		850.03 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.78
	
		P/E (F1)
		0.00
	
		Current Year Est.
		-0.08
	
		Quarterly Earnings ESP 
		-75.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		110 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/1/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.08
                        
                            Current Quarter Estimate
                            -0.08
                        
                            Most Accurate Estimate
                            -0.14
                        
                            Earnings ESP 
                            -75.00%
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            1.65
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets products for urology and sexual health. Auxilium markets Testim 1%, a topical testosterone gel, for the treatment of hypogonadism. Auxilium is developing additional Testim line extensions, as well as other products for urology and sexual health, including an enzyme in Phase II for the treatment of Peyronie's Disease that may also prove useful for the treatment of Dupuytren's Disease.   
Full AUXL Company Report

 Analyst Report on AUXL

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
AUXL Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.08	0.00	-0.08	0.72
Number of Estimates	2	2	4	5
Low Estimate	-0.14	-0.08	-0.51	-0.60
High Estimate	-0.02	0.07	0.16	NA
Year Ago EPS	0.16	-0.21	1.74	-0.08
EPS Growth	-150.00%	97.62%	-104.74%	967.88%

More AUXL Estimates

Average Earnings Estimates for AUXL

EPS Growth for AUXL

Industry Analysis

Name	Symbol	Previous Close
AUXILIUM PHARMA	AUXL	17.24
JAZZ PHARMACEUT	JAZZ	69.50
SALIX PHARM-LTD	SLXP	66.21
SANTARUS INC	SNTS	21.52
USANA HLTH SCI	USNA	73.28
ARADIGM CORP	ARDM	0.18
CELL THERAPEUT	CTIC	1.25
DURECT CORP	DRRX	0.81
ELAN CP PLC ADR	ELN	13.49
FLAMEL TECH	FLML	6.21

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Wider Loss at Auxilium, Acquires Actient

Apr 30, 2013

Positive Data on BSTC's Xiaflex

Apr 01, 2013

Actavis Files ANDA for Endo Product

Mar 05, 2013

Auxilium Beats on All Fronts

Mar 01, 2013

Zacks Rank #5 Additions for Tuesday

Feb 12, 2013

Data on Auxilium's Xiaflex

Feb 07, 2013

Zacks Bull and Bear of the Day Highlights: WisdomTree Investments, Joseph A. Bank, Auxilium Pharmaceuticals, Actavis and GlaxoSmithKline

Feb 01, 2013

Repros Delays ZA-301 Study Results

Jan 31, 2013

More AUXL Zacks Commentary

Financials

EPS TTM	1.65
Sales	395
Net Income	80
Price/Earnings	10.45
Price/Book	3.66
Price/Cash Flow	8.16
Price/Sales	2.19

More AUXL Financials

News

Stock Investors Sell Off Shares of Auxilium Pharmaceuticals, Down 1.6% - Financial News Network Online - Market Movers

Jun 18, 2013

Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of Elan (ELN, AUXL, JAZZ, QCOR, MYL) - Financial News Network Online - News Corner

Jun 17, 2013

Auxilium Pharmaceuticals Makes a Move: Up 1.7% - Financial News Network Online - Market Movers

Jun 14, 2013

Identifying the Biggest Gem in Antares`s Pipeline - TheMotleyFool

Jun 13, 2013

Auxilium Pharmaceuticals Up 14.6% Since Leerink Upgraded One Week Ago (AUXL) - Financial News Network Online - News Corner

Jun 12, 2013

Relatively Good Performance Detected in Shares of Questcor Pharmaceuticals in the Pharmaceuticals Industry (QCOR, SLXP, NKTR, VVUS, AUXL) - Financial News Network Online - News Corner

Jun 12, 2013

Men's Health Network And Auxilium Pharmaceuticals, Inc. Mark Men's Health Month With "Ask About The Curve(TM)" Collaboration To Encourage Greater Understanding Of Peyronie's Disease - Pr Newswire

Jun 11, 2013

Stock Investors Bid Up Shares of Auxilium Pharmaceuticals, Up 1.9% - Financial News Network Online - Market Movers

Jun 10, 2013

See All News Stories on AUXL

Broker Recommendations

Current ABR	1.54
ABR (Last Week)	1.54
# of recs in ABR	13
Average Target Price	20.82
Industry Rank by ABR	110 out of 265
Rank in Industry	18 out of 95

More AUXL Broker Recommendations

Day Low - High	16.95 - 17.39
52wk Low - High	13.87 - 29.37
Previous Close	17.24
Avg. Volume	771,252
Industry	MED-DRUGS
Market Cap	850.03 M
Div - Yield	0.00 - 0.00
Beta	0.78
P/E (F1)	0.00
Current Year Est.	-0.08
Quarterly Earnings ESP	-75.00%

P/E (F1)	NA
PEG Ratio	NA
Current Year Est.	-0.08
Current Quarter Estimate	-0.08
Most Accurate Estimate	-0.14
Earnings ESP	-75.00%
Next Earnings Report Date	08-06-2013
EPS Last Year	1.65
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Auxilium Pharmaceuticals Inc: (NASD: AUXL)

$17.34

0.10 (0.58%)

Volume 588,146

Jun 18 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description